Background
A Widely Used Contraceptive Now Linked to Brain Tumors
Depo-Provera is a brand name for medroxyprogesterone acetate (DMPA), a hormonal
contraceptive administered as an injection every three months. Manufactured by
Pfizer (formerly Pharmacia & Upjohn), it has been prescribed
to millions of women in the United States since receiving FDA approval in 1992.
For decades, Depo-Provera was considered a safe, convenient long-term birth control
option — particularly for women who could not tolerate estrogen-based contraceptives.
It works by releasing synthetic progestin that suppresses ovulation.
However, emerging research — including a landmark 2024 study published in
the British Medical Journal — established a significant statistical link
between prolonged Depo-Provera use and the development of meningioma:
a brain tumor that grows on the membranes surrounding the brain and spinal cord.
While often classified as benign, meningiomas can cause severe neurological damage
and frequently require surgery.
Women who used Depo-Provera for five or more years were found to have a meningioma
risk more than five times higher than non-users. Many required brain surgery and
experienced life-altering symptoms — including vision loss, headaches, cognitive
decline, and loss of motor function.
Important: Pfizer has faced allegations that it failed to
adequately warn patients and healthcare providers of this risk, despite access
to data suggesting the connection. If you used Depo-Provera and were later
diagnosed with a meningioma, you may be entitled to significant
financial compensation.